Teachers Retirement System of The State of Kentucky Grows Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Teachers Retirement System of The State of Kentucky increased its stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 37.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 72,100 shares of the biotechnology company's stock after purchasing an additional 19,708 shares during the quarter. Teachers Retirement System of The State of Kentucky's holdings in ADMA Biologics were worth $1,237,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. GAMMA Investing LLC raised its holdings in shares of ADMA Biologics by 106.6% during the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock valued at $32,000 after buying an additional 967 shares in the last quarter. Mark Sheptoff Financial Planning LLC purchased a new position in shares of ADMA Biologics during the 4th quarter valued at about $35,000. Vision Financial Markets LLC purchased a new position in shares of ADMA Biologics during the 4th quarter valued at about $51,000. AlphaQuest LLC purchased a new position in shares of ADMA Biologics during the 4th quarter valued at about $84,000. Finally, CIBC Private Wealth Group LLC raised its holdings in shares of ADMA Biologics by 137.1% during the 4th quarter. CIBC Private Wealth Group LLC now owns 5,108 shares of the biotechnology company's stock valued at $95,000 after buying an additional 2,954 shares in the last quarter. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reiterated an "overweight" rating and issued a $25.00 price objective on shares of ADMA Biologics in a research report on Tuesday, March 4th.

ADMA Biologics Stock Down 2.2 %

Shares of ADMA traded down $0.53 on Thursday, reaching $23.27. The stock had a trading volume of 2,782,071 shares, compared to its average volume of 3,685,790. The firm has a market capitalization of $5.53 billion, a price-to-earnings ratio of 83.11 and a beta of 0.53. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The company has a 50-day simple moving average of $19.29 and a 200-day simple moving average of $18.40. ADMA Biologics, Inc. has a 12-month low of $6.52 and a 12-month high of $25.67.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.